{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:28:05Z","timestamp":1777530485967,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Relypsa, Inc., a Vifor Pharma Group Company"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Hyperkalemia (potassium &gt;5.0 mEq\/L) affects heart failure patients with renal disease regardless of the use of renin\u2013angiotensin\u2013aldosterone system inhibitors (RAASi). The open-label TOURMALINE study showed that patiromer, a sodium-free, nonabsorbed potassium binder, lowers serum potassium of hyperkalemic patients similarly when given with or without food; unlike prior studies, patients were not required to be taking RAASi. We conducted post hoc analyses to provide the first report of patiromer in patients not taking RAASi.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Hyperkalemic patients received patiromer, 8.4 g\/d to start, adjusted to achieve and maintain serum potassium of 3.8 to 5.0 mEq\/L. If taking RAASi, stable doses were required. The primary end point was the proportion of patients with serum potassium 3.8 to 5.0 mEq\/L at week 3 or 4. This analysis presents data by patients taking or not taking RAASi.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Demographics and baseline characteristics were similar in patients taking (n = 67) and not taking RAASi (n = 45). Baseline mean (SD) serum potassium was 5.37 (0.37) mEq\/L and 5.42 (0.43) mEq\/L in patients taking and not taking RAASi, respectively. Mean (SD) daily patiromer doses were similar (10.7 [3.2] and 11.5 [4.0] g, respectively). The primary end point was achieved in 85% (95% confidence interval [CI]: 74-93) of patients taking RAASi and in 84% (95% CI: 71-94) of patients not taking RAASi. From baseline to week 4, the mean (SE) change in serum potassium was \u22120.67 (0.08) mEq\/L in patients taking RAASi and \u22120.56 (0.10) mEq\/L in patients not taking RAASi (both P &lt; .0001 vs baseline, P = nonsignificant between groups). Adverse events were reported in 26 (39%) patients taking RAASi and 25 (54%) not taking RAASi; the most common adverse event was diarrhea (2% and 11%, respectively; no cases were severe). Five patients (2 taking RAASi) reported 6 serious adverse events; none considered related to patiromer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Patiromer was effective and generally well-tolerated for hyperkalemia treatment, whether or not patients were taking RAAS inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1074248418788334","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T03:18:48Z","timestamp":1534216728000},"page":"524-531","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors"],"prefix":"10.1177","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6258-0544","authenticated-orcid":false,"given":"Robert A.","family":"Kloner","sequence":"first","affiliation":[{"name":"Huntington Medical Research Institutes, Pasadena, CA, USA"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coleman","family":"Gross","sequence":"additional","affiliation":[{"name":"Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinwei","family":"Yuan","sequence":"additional","affiliation":[{"name":"Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansgar","family":"Conrad","sequence":"additional","affiliation":[{"name":"Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo E.","family":"Pergola","sequence":"additional","affiliation":[{"name":"Renal Associates, P.A., San Antonio, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,8,14]]},"reference":[{"key":"bibr1-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.132"},{"key":"bibr2-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.07.035"},{"key":"bibr3-1074248418788334","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07821109"},{"key":"bibr4-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.014281"},{"key":"bibr5-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.01.031"},{"key":"bibr6-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"bibr7-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713"},{"key":"bibr8-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.03.007"},{"key":"bibr9-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520420066040"},{"key":"bibr10-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"bibr11-1074248418788334","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2012.717478"},{"issue":"11","key":"bibr12-1074248418788334","first-page":"S212","volume":"21","author":"Epstein M","year":"2015","journal-title":"Am J Manag Care"},{"key":"bibr13-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1177\/1074248416629549"},{"key":"bibr14-1074248418788334","unstructured":"Veltassa\u00ae (patiromer) [package insert]. Prescribing Information. Redwood City, CA: Relypsa, Inc, a Vifor Pharma Group Company; 2018. https:\/\/www.veltassa.com\/pi.pdf. Accessed July 2018."},{"key":"bibr15-1074248418788334","unstructured":"Veltassa\u00ae (patiromer) [package insert]. SmPC. European Medicines Agency. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/004180\/human_med_002141.jsp&mid=WC0b0. Accessed July 2018."},{"key":"bibr16-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.7446"},{"key":"bibr17-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410853"},{"key":"bibr18-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1159\/000481270"},{"key":"bibr19-1074248418788334","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0196-1"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248418788334","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1074248418788334","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248418788334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:42:52Z","timestamp":1777394572000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1074248418788334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,14]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1177\/1074248418788334"],"URL":"https:\/\/doi.org\/10.1177\/1074248418788334","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,14]]}}}